ArticlebioRxiv : the preprint server for biology2024
A framework for target discovery in rare cancers.
Bingchen Li, Ananthan Sadagopan, Jiao Li, Yuqianxun Wu, Yantong Cui, Prathyusha Konda, Cary N Weiss, Toni K Choueiri, John G Doench, Srinivas R Viswanathan
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Bingchen LiDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA 02215, USA.
Ananthan SadagopanDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA 02215, USA.ORCID 0000-0001-6306-4907 Yuqianxun WuDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA 02215, USA.
Yantong CuiDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA 02215, USA.
Prathyusha KondaDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA 02215, USA.
Cary N WeissDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA 02215, USA.
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA 02215, USA.
John G DoenchBroad Institute of MIT and Harvard; Cambridge, MA 02142, USA.
Srinivas R ViswanathanDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA 02215, USA.
Funding
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4MProbing the role of somatic X-chromosome alterations in shaping cancer sex differencesR01CA286652 · NCI · DANA-FARBER CANCER INST · PI VISWANATHAN, SRINIVAS RAGHAVAN, ZHANG, CHENG-ZHONG · 2023 to 2025
$2.7MMolecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinomaR01CA279044 · NCI · DANA-FARBER CANCER INST · PI Srinivas Raghavan Viswanathan · 2023 to 2026
$2.0MRegulation of androgen receptor signaling in prostate cancer by protein arginine methylationR01CA269505 · NCI · DANA-FARBER CANCER INST · PI VISWANATHAN, SRINIVAS RAGHAVAN · 2023 to 2024
$1.1MNCI NIH HHS P50 CA101942NCI NIH HHS R01 CA269505NCI NIH HHS R01 CA279044NCI NIH HHS R01 CA286652
6 · The paper itselfAbstract
While large-scale functional genetic screens have uncovered numerous cancer dependencies, rare cancers are poorly represented in such efforts and the landscape of dependencies in many rare cancers remains obscure. We performed genome-scale CRISPR knockout screens in an exemplar rare cancer,
Identifiers
PMID39484513
PMCPMC11527139
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390